Niagen Bioscience, Inc. (NAGE) has demonstrated strong top-line growth and profitability gains over recent years driven by its core nicotinamide riboside chloride (NRCL) technology. Its proprietary Niagen® ingredient supports both consumer and pharmaceutical applications, with notable expansion in finished products like Tru Niagen®. The company reported nearly $130 million revenue in 2025, a 30% increase from the prior year, alongside positive operating income of $16.3 million and net income of $17.4 million. Capital allocation has been conservative with modest buybacks and steady R&D investment focused on expanding the NAD+ precursor pipeline. Key risks include supplier concentration, competitive pressures, evolving regulations, and the challenge of sustaining growth amid market shifts. Near-term milestones to monitor include pharmaceutical segment development progress and international market expansion execution.